No Mandates Act This bill prohibits federal agencies and certain entities that receive federal funding from requiring COVID-19 vaccinations. Specifically, federal agencies may not issue rules, regulations, or guidance that require an individual to receive a COVID-19 vaccination. The bill also prohibits requiring a COVID-19 vaccination to access federal property and services or congressional grounds and services. Additionally, an entity that received federal COVID-19 relief funds or receives other federal funds after this bill's enactment may not require a COVID-19 vaccination as a condition of providing any service to an individual.
Preventing Violence Against Female Inmates Act of 2022 This bill establishes a framework to prohibit correctional institutions at the federal and state levels from using gender identity to house inmates of one biological sex with inmates of the other biological sex.
This bill nullifies Order 2021-148 of the Mayor of the District of Columbia (December 22, 2021) and any successor or substantially similar order of the Mayor of the District of Columbia that imposes a COVID-19 vaccine requirement for entry to certain establishments and facilities in the District.
This concurrent resolution authorizes the use of the Capitol rotunda on January 12, 2022, for the lying in state of the remains of the Honorable Harry Reid, Jr., late a Senator from Nevada.
This concurrent resolution directs the Architect of the Capitol to move the catafalque (a wooden platform) from the Capitol Visitor Center to the Capitol rotunda for use in connection with services for the Honorable Harry Reid, Jr., late a Senator from Nevada.
SRES 485 is a Senate resolution honoring the late Senator Harry Mason Reid, Jr., of Nevada, who died in 2021. The resolution expresses the Senate's sorrow at his passing, extends condolences to his family, and directs the Secretary of the Senate to communicate the resolution to the House of Representatives and provide a copy to Reid's family. The Senate also adjourned in his memory as a mark of respect. This is a ceremonial tribute with no policy changes or legal effect.
SRES 484 is a ceremonial Senate resolution honoring the late Senator John "Johnny" Isakson of Georgia. It formally recognizes his 40+ years of public service, including his roles in the Georgia legislature, U.S. House, and U.S. Senate, and his reputation for bipartisan cooperation. The resolution requests the Senate Secretary communicate it to the House and send a copy to Isakson's family. As a commemorative resolution, it has no policy impact or direct effect on any individuals or programs.
PrEP Access and Coverage Act This bill requires private health insurance plans to cover prescription drugs that prevent HIV, including related screenings, diagnostic procedures, administrative fees, and clinical follow-ups, without any cost-sharing obligation for the plan holder. Further, insurance plans must not impose any preauthorization requirement for this coverage. These coverage requirements also apply to public health insurance programs, including Medicare, Medicaid, and the Children's Health Insurance Program. Additionally, the bill prohibits denying, limiting, or qualifying coverage or increasing premiums for disability insurance, long-term care insurance, or life insurance policies based on an individual taking medication for HIV prevention. The bill further requires the Department of Health and Human Services to award grants to states, or directly to eligible local organizations, to provide uninsured individuals and underinsured individuals access to prescription drugs and related services that prevent HIV. The Centers for Disease Control and Prevention also must develop a public awareness campaign that focuses efforts in communities with a high need for HIV prevention treatment.
Cures 2.0 Act This bill addresses pandemic preparedness and public health issues, caregiver and patient engagement, drug development, insurance coverage, and biomedical research. The Department of Health and Human Services (HHS) must undertake research and other activities concerning COVID-19 and develop a strategy for future pandemics and declared emergencies. Additionally, the bill specifies actions to combat antimicrobial resistance. HHS may award grants for caregiver training. The bill also addresses diversity in clinical trials, collecting patient experience data during clinical trials, and coverage for care related to participation in specified clinical trials. The bill modifies the timeframe and requires additional guidance relating to expedited approval of certain breakthrough drugs, devices, or products. It also establishes two intercenter institutes within the Food and Drug Administration (FDA) focused on particular diseases that meet specified criteria. The bill also addresses (1) coverage in Medicare, Medicaid, and the Children's Health Insurance Program for telehealth, genetic and genomic testing, and other services; (2) electronic prescribing standards for Medicare drug benefits; and (3) access to Medicare and Medicaid claims data by certain registries. Furthermore, the bill prohibits the use of geographic tracking or biometrics in Medicaid electronic visit verification systems. The bill establishes the Advanced Research Projects Agency for Health (ARPA-H) within the National Institutes of Health to accelerate biomedical research and innovation through grants, contracts, cash prizes, and other means. The FDA may work with ARPA-H to expedite the development of medical products through specified activities.
Protecting Horses from Soring Act of 2021 This bill revises requirements concerning the inspection of horse shows, exhibitions, sales, and actions for sored horses (e.g., horses suffering from pain when moving due to substances or devices placed on their limbs). Specifically, this bill replaces a requirement for the Department of Agriculture to prescribe regulations governing the appointment of inspectors with a requirement for the Horse Industry Organization, which is established by this bill, to appoint inspectors.
Accelerating Access to Critical Therapies for ALS Act This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions. The Department of Health and Human Services (HHS) shall award grants to eligible entities for scientific research utilizing data from expanded access to investigational ALS treatments for individuals who are not otherwise eligible for clinical trials. The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other rare neurodegenerative diseases. HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases. The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases. The Government Accountability Office must report to Congress about the grants provided under this bill, including an analysis of the impact of such grants on research and development of treatments for ALS.
Reforming Broadband Connectivity Act of 2021 This bill requires the Federal Communications Commission (FCC) to make changes to the financing of the Universal Service Fund. This fund, which is financed by fees contributed by telecommunications carriers, supports programs to expand the availability of and access to telecommunications services. Specifically, the bill directs the FCC to (1) study the need for expanding the fund's contribution base to ensure fairness and equity in applicable contribution requirements, and (2) reform the fund's contribution system through rulemaking. In carrying out the rulemaking, the FCC must consider the findings and recommendations of its study and the impact of changes on consumers, businesses, and seniors.
